| In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities C Rubio-Perez, D Tamborero, MP Schroeder, AA Antolín, J Deu-Pons, ... Cancer cell 27 (3), 382-396, 2015 | 345 | 2015 |
| Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen MP Menden, D Wang, MJ Mason, B Szalai, KC Bulusu, Y Guan, T Yu, ... Nature communications 10 (1), 2674, 2019 | 325 | 2019 |
| The kinase polypharmacology landscape of clinical PARP inhibitors AA Antolin, M Ameratunga, U Banerji, PA Clarke, P Workman, ... Scientific reports 10 (1), 2585, 2020 | 109 | 2020 |
| canSAR: an updated cancer research and drug discovery knowledgebase JE Tym, C Mitsopoulos, EA Coker, P Razaz, AC Schierz, AA Antolin, ... Nucleic acids research 44 (D1), D938-D943, 2016 | 109 | 2016 |
| canSAR: update to the cancer translational research and drug discovery knowledgebase C Mitsopoulos, P Di Micco, EV Fernandez, D Dolciami, E Holt, IL Mica, ... Nucleic acids research 49 (D1), D1074-D1082, 2021 | 93 | 2021 |
| Polypharmacology in precision oncology: current applications and future prospects A A. Antolin, P Workman, J Mestres, B Al-Lazikani Current pharmaceutical design 22 (46), 6935-6945, 2016 | 91 | 2016 |
| Identification of pim kinases as novel targets for PJ34 with confounding effects in PARP biology AA Antolin, X Jalencas, J Yelamos, J Mestres ACS chemical biology 7 (12), 1962-1967, 2012 | 82 | 2012 |
| Objective, quantitative, data-driven assessment of chemical probes AA Antolin, JE Tym, A Komianou, I Collins, P Workman, B Al-Lazikani Cell chemical biology 25 (2), 194-205. e5, 2018 | 81 | 2018 |
| Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors AA Antolín, J Mestres Oncotarget 5 (10), 3023, 2014 | 70 | 2014 |
| Target 2035–update on the quest for a probe for every protein S Müller, S Ackloo, A Al Chawaf, B Al-Lazikani, A Antolin, JB Baell, ... RSC Medicinal Chemistry 13 (1), 13-21, 2022 | 64 | 2022 |
| canSAR: update to the cancer translational research and drug discovery knowledgebase EA Coker, C Mitsopoulos, JE Tym, A Komianou, C Kannas, P Di Micco, ... Nucleic acids research 47 (D1), D917-D922, 2019 | 62 | 2019 |
| Identification of different side effects between PARP inhibitors and their polypharmacological multi‐target rationale D Sandhu, AA Antolin, AR Cox, AM Jones British journal of clinical pharmacology 88 (2), 742-752, 2022 | 57 | 2022 |
| Transforming cancer drug discovery with Big Data and AI P Workman, AA Antolin, B Al-Lazikani Expert opinion on drug discovery 14 (11), 1089-1095, 2019 | 44 | 2019 |
| The Chemical Probes Portal: an expert review-based public resource to empower chemical probe assessment, selection and use AA Antolin, D Sanfelice, A Crisp, E Villasclaras Fernandez, IL Mica, ... Nucleic acids research 51 (D1), D1492-D1502, 2023 | 40 | 2023 |
| Public resources for chemical probes: the journey so far and the road ahead AA Antolin, P Workman, B Al-Lazikani Future Medicinal Chemistry 13 (08), 731-747, 2021 | 32 | 2021 |
| Distant polypharmacology among MLP chemical probes AA Antolin, J Mestres Acs Chemical Biology 10 (2), 395-400, 2015 | 32 | 2015 |
| canSAR: update to the cancer translational research and drug discovery knowledgebase P Di Micco, AA Antolin, C Mitsopoulos, E Villasclaras-Fernandez, ... Nucleic acids research 51 (D1), D1212-D1219, 2023 | 24 | 2023 |
| Exploring the effect of PARP-1 flexibility in docking studies AA Antolin, A Carotti, R Nuti, A Hakkaya, E Camaioni, J Mestres, ... Journal of Molecular Graphics and Modelling 45, 192-201, 2013 | 18 | 2013 |
| Evolution of kinase polypharmacology across HSP90 drug discovery AA Antolin, PA Clarke, I Collins, P Workman, B Al-Lazikani Cell Chemical Biology 28 (10), 1433-1445. e3, 2021 | 17 | 2021 |
| canSAR chemistry registration and standardization pipeline D Dolciami, E Villasclaras-Fernandez, C Kannas, M Meniconi, ... Journal of Cheminformatics 14 (1), 28, 2022 | 15 | 2022 |
Bissan Al-LazikaniProfessor, Genomic Medicine; Director Therapeutics Data ScienceVerified email at mdanderson.org